Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

ISARIC has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study. The patient survey has been designed to assess long-term health and psychosocial consequences of COVID-19 at serial intervals for up to three to five years, depending on resources.

Two researchers in hazmat suit discussing a sample in front of a sign COVID quarantine

The survey has been developed to allow patients to complete by self-assessment online, or via post, or during a telephone or in-clinic assessment. This dedicated form is especially designed for collecting data on health and psychosocial complications. It may be used on its own for data collection, or in combination with sampling for immunology, pathophysiology and other studies.

The ISARIC Global COVID-19 follow-up working group is led by Dr Janet Scott, of the MRC-University of Glasgow’s Centre for Virus Research. The study protocol and associated patient survey has been developed in collaboration with the ISARIC global COVID-19 follow-up working group, which includes clinicians and research colleagues from Brazil, Canada, Colombia, France, Ghana, Italy, Norway, Pakistan, Russia, Sierra Leone  and a wide range of experts in infectious diseases, rheumatology, neurology, intensive care, oncology, public health, psychology and rehabilitation. 

Dr Scott said: “It is vitally important that we are able to understand the long-term risk factors and health conditions associated with COVID-19, in order to ensure we are delivering the very best healthcare to patients in the long term”. “In order to do this, the assessment of risk factors for longer term consequences requires a longitudinal study, with data on pre-existing conditions and care received during the acute phase of the COVID-19 illness all linked together.”

Dr Daniel Munblit, Associate Professor, Sechenov University, Russia says “researchers in the international working group, from across the world have been able to meet on virtual platforms and have together developed these research tools which we can then make open access to all of our Global partners. International collaboration is really now coming into its own.”

Louise Sigfrid (ISARIC) said “Currently, very little is known about possible clinical and psychosocial sequelae that may persist in patients after recovering from acute COVID-19  A  recent study from Italy of 143 patients after hospitalisation with COVID-19, showed that 87% had at least one ongoing symptom after 60 days. It will be interesting to see what results come from larger groups of patients from different populations.”

Dr Luis Felipe Reyes, Head of the Infectious Diseases Department, Universidad de La Sabana, Colombia, says: “Long term implications of pulmonary infections have been well known for several years. Physicians often believe that the implications of lower respiratory tract infections end when patients survive the acute infection. However, this initial insult to the lungs causes cardiovascular complications, disability, and overall increased mortality up to 10 years after the acute episode. Therefore, understanding the factors associated with the long-term consequences of COVID-19 may help clinicians to prevent these complications, improving the quality of life of COVID-19 survivors. This study will bring generalizable data to the world and important implications for science and patient care”.

The follow-up data will be linked to acute-phase data from a sub-set of patients in the cohort of more than 85,000 in-patients (as of 20 July 2020) with COVID-19 documented in the ISARIC COVID-19 database. By standardising data collection tools it will enable combined analysis across multiple-sites. The tools are open-access and we encourage sites globally to adopt and adapt the tools to their context.

This collaborative, open access study aims to characterise the frequency of and risk factors for long term consequences from COVID-19. It will also characterise the immune response over time in patients following a diagnosis of COVID-19 and facilitate standardised and longitudinal data collection globally.

If your hospital or healthcare site wishes to participate in this study, please contact Louise Sigfrid

Read the publication Sigfrid, Cevik et al., What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study, MedRxiv, 1 Sept. 2020

ISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases. ISARIC’s mission is to generate and disseminate clinical research evidence for outbreak-prone infectious diseases, whenever and wherever they occur.

 Funded by the Wellcome Trust, the UK Department for International Development, and the Bill & Melinda Gates Foundation.

Similar stories

World’s largest clinical trial for COVID-19 treatments expands internationally

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Geneva Health Forum panel on the elimination of NTDs and the new WHO Roadmap

Conferences & meetings OCGHR

The WHO 2030 NTD Roadmap has just been launched, and a recent Geneva Health Forum panel took that as its starting point to discuss the possibility of eliminating neglected tropical diseases (NTDs). Professor Philippe Guérin, IDDO’s Director, joined co-panellists Dr Amy Fall, the Global Health Medical for Africa Region Lead at Sanofi, Dr Mwele Malecela, Director of the Department of Control of Neglected Tropical Diseases at the WHO, and Dr Nathalie Strub-Wourgaft, Medical Director at Drugs for Neglected Diseases initiative (DNDi) back in November 2020.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

OCGHR Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.